nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbamazepine—UGT2B7—Mycophenolic acid—psoriasis	0.0952	0.13	CbGbCtD
Carbamazepine—UGT2B7—Mycophenolate mofetil—psoriasis	0.0532	0.0729	CbGbCtD
Carbamazepine—CYP2C8—Tazarotene—psoriasis	0.0364	0.0499	CbGbCtD
Carbamazepine—CYP3A5—Beclomethasone—psoriasis	0.0352	0.0482	CbGbCtD
Carbamazepine—CYP1A2—Clobetasol propionate—psoriasis	0.0346	0.0473	CbGbCtD
Carbamazepine—ABCC2—Mycophenolate mofetil—psoriasis	0.028	0.0383	CbGbCtD
Carbamazepine—ABCC2—Cyclosporine—psoriasis	0.0212	0.029	CbGbCtD
Carbamazepine—CYP2B6—Cholecalciferol—psoriasis	0.0205	0.0281	CbGbCtD
Carbamazepine—CYP1A2—Methoxsalen—psoriasis	0.0182	0.0249	CbGbCtD
Carbamazepine—CYP2C8—Cholecalciferol—psoriasis	0.0155	0.0213	CbGbCtD
Carbamazepine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.015	0.0205	CbGbCtD
Carbamazepine—CYP3A7—Hydrocortisone—psoriasis	0.015	0.0205	CbGbCtD
Carbamazepine—CYP3A7—Cyclosporine—psoriasis	0.0142	0.0194	CbGbCtD
Carbamazepine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0142	0.0194	CbGbCtD
Carbamazepine—CYP3A5—Mycophenolate mofetil—psoriasis	0.014	0.0192	CbGbCtD
Carbamazepine—ABCC2—Dexamethasone—psoriasis	0.014	0.0191	CbGbCtD
Carbamazepine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0135	0.0185	CbGbCtD
Carbamazepine—CYP2C19—Cholecalciferol—psoriasis	0.013	0.0179	CbGbCtD
Carbamazepine—CYP3A4—Calcitriol—psoriasis	0.0122	0.0168	CbGbCtD
Carbamazepine—CYP3A5—Hydrocortisone—psoriasis	0.0112	0.0154	CbGbCtD
Carbamazepine—ABCC2—Methotrexate—psoriasis	0.0112	0.0154	CbGbCtD
Carbamazepine—CYP2C9—Cholecalciferol—psoriasis	0.0108	0.0148	CbGbCtD
Carbamazepine—CYP2C8—Hydrocortisone—psoriasis	0.0108	0.0148	CbGbCtD
Carbamazepine—CYP3A5—Cyclosporine—psoriasis	0.0106	0.0145	CbGbCtD
Carbamazepine—CYP2C8—Cyclosporine—psoriasis	0.0102	0.014	CbGbCtD
Carbamazepine—CYP3A4—Methoxsalen—psoriasis	0.00951	0.013	CbGbCtD
Carbamazepine—CYP3A7—Dexamethasone—psoriasis	0.00932	0.0128	CbGbCtD
Carbamazepine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00932	0.0128	CbGbCtD
Carbamazepine—ABCB1—Mycophenolate mofetil—psoriasis	0.00912	0.0125	CbGbCtD
Carbamazepine—CYP2C19—Prednisone—psoriasis	0.00904	0.0124	CbGbCtD
Carbamazepine—CYP2B6—Dexamethasone—psoriasis	0.00888	0.0122	CbGbCtD
Carbamazepine—CYP2C19—Cyclosporine—psoriasis	0.00857	0.0117	CbGbCtD
Carbamazepine—ABCB1—Betamethasone—psoriasis	0.00783	0.0107	CbGbCtD
Carbamazepine—ABCB1—Prednisolone—psoriasis	0.00772	0.0106	CbGbCtD
Carbamazepine—ABCB1—Hydrocortisone—psoriasis	0.00732	0.01	CbGbCtD
Carbamazepine—ABCB1—Prednisone—psoriasis	0.00729	0.00998	CbGbCtD
Carbamazepine—CYP2C9—Cyclosporine—psoriasis	0.00712	0.00975	CbGbCtD
Carbamazepine—CYP3A5—Dexamethasone—psoriasis	0.00699	0.00958	CbGbCtD
Carbamazepine—ABCB1—Cyclosporine—psoriasis	0.00691	0.00947	CbGbCtD
Carbamazepine—CYP2C8—Dexamethasone—psoriasis	0.00672	0.00921	CbGbCtD
Carbamazepine—CYP3A4—Cholecalciferol—psoriasis	0.0063	0.00863	CbGbCtD
Carbamazepine—CYP2C19—Dexamethasone—psoriasis	0.00564	0.00773	CbGbCtD
Carbamazepine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00546	0.00748	CbGbCtD
Carbamazepine—CYP3A4—Triamcinolone—psoriasis	0.00546	0.00748	CbGbCtD
Carbamazepine—CYP2C9—Dexamethasone—psoriasis	0.00469	0.00642	CbGbCtD
Carbamazepine—CYP3A4—Betamethasone—psoriasis	0.00469	0.00642	CbGbCtD
Carbamazepine—CYP3A4—Prednisolone—psoriasis	0.00463	0.00633	CbGbCtD
Carbamazepine—ABCB1—Dexamethasone—psoriasis	0.00455	0.00623	CbGbCtD
Carbamazepine—CYP3A4—Hydrocortisone—psoriasis	0.00439	0.00601	CbGbCtD
Carbamazepine—CYP3A4—Prednisone—psoriasis	0.00437	0.00598	CbGbCtD
Carbamazepine—CYP3A4—Cyclosporine—psoriasis	0.00414	0.00567	CbGbCtD
Carbamazepine—ABCB1—Methotrexate—psoriasis	0.00366	0.00501	CbGbCtD
Carbamazepine—CYP3A4—Dexamethasone—psoriasis	0.00273	0.00373	CbGbCtD
Carbamazepine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00101	0.0347	CbGpPWpGaD
Carbamazepine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000923	0.0316	CbGpPWpGaD
Carbamazepine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00083	0.0285	CbGpPWpGaD
Carbamazepine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000811	0.0278	CbGpPWpGaD
Carbamazepine—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000703	0.0241	CbGpPWpGaD
Carbamazepine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000627	0.0215	CbGpPWpGaD
Carbamazepine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000572	0.0196	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000491	0.0168	CbGpPWpGaD
Carbamazepine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000489	0.0168	CbGpPWpGaD
Carbamazepine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000466	0.016	CbGpPWpGaD
Carbamazepine—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00046	0.0158	CbGpPWpGaD
Carbamazepine—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000432	0.0148	CbGpPWpGaD
Carbamazepine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000378	0.013	CbGpPWpGaD
Carbamazepine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000377	0.0129	CbGpPWpGaD
Carbamazepine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000345	0.0118	CbGpPWpGaD
Carbamazepine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00034	0.0117	CbGpPWpGaD
Carbamazepine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000337	0.0116	CbGpPWpGaD
Carbamazepine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000333	0.0114	CbGpPWpGaD
Carbamazepine—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000294	0.0101	CbGpPWpGaD
Carbamazepine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000292	0.01	CbGpPWpGaD
Carbamazepine—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.00029	0.00993	CbGpPWpGaD
Carbamazepine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000288	0.00987	CbGpPWpGaD
Carbamazepine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000279	0.00958	CbGpPWpGaD
Carbamazepine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000273	0.00936	CbGpPWpGaD
Carbamazepine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00026	0.00893	CbGpPWpGaD
Carbamazepine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000257	0.00881	CbGpPWpGaD
Carbamazepine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000248	0.00851	CbGpPWpGaD
Carbamazepine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000238	0.00814	CbGpPWpGaD
Carbamazepine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000237	0.00811	CbGpPWpGaD
Carbamazepine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000234	0.00804	CbGpPWpGaD
Carbamazepine—RALBP1—EGF/EGFR Signaling Pathway—PCNA—psoriasis	0.000219	0.00751	CbGpPWpGaD
Carbamazepine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000211	0.00724	CbGpPWpGaD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000206	0.00705	CbGpPWpGaD
Carbamazepine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000203	0.00697	CbGpPWpGaD
Carbamazepine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000203	0.00696	CbGpPWpGaD
Carbamazepine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000201	0.00688	CbGpPWpGaD
Carbamazepine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.0002	0.00687	CbGpPWpGaD
Carbamazepine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000198	0.00679	CbGpPWpGaD
Carbamazepine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000193	0.0066	CbGpPWpGaD
Carbamazepine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000173	0.00594	CbGpPWpGaD
Carbamazepine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000165	0.00564	CbGpPWpGaD
Carbamazepine—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000164	0.00561	CbGpPWpGaD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000162	0.00557	CbGpPWpGaD
Carbamazepine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000158	0.00543	CbGpPWpGaD
Carbamazepine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000157	0.00537	CbGpPWpGaD
Carbamazepine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000155	0.0053	CbGpPWpGaD
Carbamazepine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000148	0.00509	CbGpPWpGaD
Carbamazepine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000146	0.00502	CbGpPWpGaD
Carbamazepine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000145	0.00497	CbGpPWpGaD
Carbamazepine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000143	0.00491	CbGpPWpGaD
Carbamazepine—ABCC2—NRF2 pathway—TGFA—psoriasis	0.00013	0.00444	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—HCAR2—psoriasis	0.000128	0.00437	CbGpPWpGaD
Carbamazepine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000127	0.00435	CbGpPWpGaD
Carbamazepine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000126	0.00431	CbGpPWpGaD
Carbamazepine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000125	0.00429	CbGpPWpGaD
Carbamazepine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000124	0.00425	CbGpPWpGaD
Carbamazepine—RALBP1—EGF/EGFR Signaling Pathway—JUN—psoriasis	0.000122	0.00418	CbGpPWpGaD
Carbamazepine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000121	0.00413	CbGpPWpGaD
Carbamazepine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000117	0.004	CbGpPWpGaD
Carbamazepine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000112	0.00385	CbGpPWpGaD
Carbamazepine—SCN9A—Developmental Biology—CARM1—psoriasis	0.000112	0.00383	CbGpPWpGaD
Carbamazepine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000111	0.00379	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—TAGAP—psoriasis	0.000111	0.00379	CbGpPWpGaD
Carbamazepine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00011	0.00378	CbGpPWpGaD
Carbamazepine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000109	0.00374	CbGpPWpGaD
Carbamazepine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000109	0.00373	CbGpPWpGaD
Carbamazepine—RALBP1—EGF/EGFR Signaling Pathway—STAT3—psoriasis	0.000106	0.00362	CbGpPWpGaD
Carbamazepine—SCN4A—Developmental Biology—CARM1—psoriasis	0.000103	0.00352	CbGpPWpGaD
Carbamazepine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000102	0.00351	CbGpPWpGaD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—IL10—psoriasis	0.000102	0.00348	CbGpPWpGaD
Carbamazepine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000101	0.00346	CbGpPWpGaD
Carbamazepine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.95e-05	0.00341	CbGpPWpGaD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.74e-05	0.00334	CbGpPWpGaD
Carbamazepine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.32e-05	0.0032	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—HLA-C—psoriasis	9.31e-05	0.00319	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—IL13—psoriasis	9.25e-05	0.00317	CbGpPWpGaD
Carbamazepine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.74e-05	0.003	CbGpPWpGaD
Carbamazepine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.62e-05	0.00296	CbGpPWpGaD
Carbamazepine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.61e-05	0.00295	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—IL17A—psoriasis	8.51e-05	0.00292	CbGpPWpGaD
Carbamazepine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.47e-05	0.00291	CbGpPWpGaD
Carbamazepine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.14e-05	0.00279	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—IL12B—psoriasis	7.92e-05	0.00271	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—HLA-E—psoriasis	7.73e-05	0.00265	CbGpPWpGaD
Carbamazepine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.61e-05	0.00261	CbGpPWpGaD
Carbamazepine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.54e-05	0.00258	CbGpPWpGaD
Carbamazepine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.2e-05	0.00247	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—CARM1—psoriasis	6.96e-05	0.00238	CbGpPWpGaD
Carbamazepine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.75e-05	0.00231	CbGpPWpGaD
Carbamazepine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.65e-05	0.00228	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—CCL20—psoriasis	6.63e-05	0.00227	CbGpPWpGaD
Carbamazepine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.5e-05	0.00223	CbGpPWpGaD
Carbamazepine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.47e-05	0.00222	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.39e-05	0.00219	CbGpPWpGaD
Carbamazepine—Myalgia—Betamethasone—psoriasis	5.96e-05	0.000248	CcSEcCtD
Carbamazepine—Body temperature increased—Cyclosporine—psoriasis	5.95e-05	0.000247	CcSEcCtD
Carbamazepine—Abdominal pain—Cyclosporine—psoriasis	5.95e-05	0.000247	CcSEcCtD
Carbamazepine—Anxiety—Dexamethasone—psoriasis	5.94e-05	0.000247	CcSEcCtD
Carbamazepine—Anxiety—Betamethasone—psoriasis	5.94e-05	0.000247	CcSEcCtD
Carbamazepine—Vomiting—Mycophenolic acid—psoriasis	5.92e-05	0.000246	CcSEcCtD
Carbamazepine—UGT2B7—Metabolism—NDUFA5—psoriasis	5.91e-05	0.00203	CbGpPWpGaD
Carbamazepine—Dyspepsia—Hydrocortisone—psoriasis	5.89e-05	0.000245	CcSEcCtD
Carbamazepine—Rash—Mycophenolic acid—psoriasis	5.87e-05	0.000244	CcSEcCtD
Carbamazepine—Dermatitis—Mycophenolic acid—psoriasis	5.86e-05	0.000244	CcSEcCtD
Carbamazepine—Pain—Prednisolone—psoriasis	5.86e-05	0.000244	CcSEcCtD
Carbamazepine—Hepatitis—Methotrexate—psoriasis	5.86e-05	0.000244	CcSEcCtD
Carbamazepine—Urticaria—Mycophenolate mofetil—psoriasis	5.84e-05	0.000243	CcSEcCtD
Carbamazepine—Headache—Mycophenolic acid—psoriasis	5.83e-05	0.000242	CcSEcCtD
Carbamazepine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.82e-05	0.002	CbGpPWpGaD
Carbamazepine—Decreased appetite—Hydrocortisone—psoriasis	5.82e-05	0.000242	CcSEcCtD
Carbamazepine—Pharyngitis—Methotrexate—psoriasis	5.81e-05	0.000242	CcSEcCtD
Carbamazepine—Abdominal pain—Mycophenolate mofetil—psoriasis	5.81e-05	0.000241	CcSEcCtD
Carbamazepine—Body temperature increased—Mycophenolate mofetil—psoriasis	5.81e-05	0.000241	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—IL10—psoriasis	5.79e-05	0.00198	CbGpPWpGaD
Carbamazepine—Urinary tract disorder—Methotrexate—psoriasis	5.78e-05	0.00024	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.78e-05	0.00024	CcSEcCtD
Carbamazepine—Fatigue—Hydrocortisone—psoriasis	5.77e-05	0.00024	CcSEcCtD
Carbamazepine—Vision blurred—Prednisone—psoriasis	5.75e-05	0.000239	CcSEcCtD
Carbamazepine—Urethral disorder—Methotrexate—psoriasis	5.74e-05	0.000239	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.74e-05	0.000239	CcSEcCtD
Carbamazepine—Pain—Hydrocortisone—psoriasis	5.72e-05	0.000238	CcSEcCtD
Carbamazepine—Anaphylactic shock—Dexamethasone—psoriasis	5.72e-05	0.000238	CcSEcCtD
Carbamazepine—Oedema—Dexamethasone—psoriasis	5.72e-05	0.000238	CcSEcCtD
Carbamazepine—Anaphylactic shock—Betamethasone—psoriasis	5.72e-05	0.000238	CcSEcCtD
Carbamazepine—Oedema—Betamethasone—psoriasis	5.72e-05	0.000238	CcSEcCtD
Carbamazepine—SCN9A—Axon guidance—TYK2—psoriasis	5.71e-05	0.00196	CbGpPWpGaD
Carbamazepine—Insomnia—Triamcinolone—psoriasis	5.7e-05	0.000237	CcSEcCtD
Carbamazepine—Infection—Betamethasone—psoriasis	5.68e-05	0.000236	CcSEcCtD
Carbamazepine—Infection—Dexamethasone—psoriasis	5.68e-05	0.000236	CcSEcCtD
Carbamazepine—Paraesthesia—Triamcinolone—psoriasis	5.66e-05	0.000235	CcSEcCtD
Carbamazepine—Feeling abnormal—Prednisolone—psoriasis	5.65e-05	0.000235	CcSEcCtD
Carbamazepine—Anaemia—Prednisone—psoriasis	5.64e-05	0.000234	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—IL4—psoriasis	5.63e-05	0.00193	CbGpPWpGaD
Carbamazepine—Shock—Betamethasone—psoriasis	5.63e-05	0.000234	CcSEcCtD
Carbamazepine—Shock—Dexamethasone—psoriasis	5.63e-05	0.000234	CcSEcCtD
Carbamazepine—Dyspnoea—Triamcinolone—psoriasis	5.62e-05	0.000234	CcSEcCtD
Carbamazepine—Nervous system disorder—Betamethasone—psoriasis	5.61e-05	0.000233	CcSEcCtD
Carbamazepine—Nervous system disorder—Dexamethasone—psoriasis	5.61e-05	0.000233	CcSEcCtD
Carbamazepine—Agitation—Prednisone—psoriasis	5.61e-05	0.000233	CcSEcCtD
Carbamazepine—Thrombocytopenia—Dexamethasone—psoriasis	5.6e-05	0.000233	CcSEcCtD
Carbamazepine—Thrombocytopenia—Betamethasone—psoriasis	5.6e-05	0.000233	CcSEcCtD
Carbamazepine—Tachycardia—Dexamethasone—psoriasis	5.58e-05	0.000232	CcSEcCtD
Carbamazepine—Tachycardia—Betamethasone—psoriasis	5.58e-05	0.000232	CcSEcCtD
Carbamazepine—Angioedema—Prednisone—psoriasis	5.58e-05	0.000232	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.56e-05	0.0019	CbGpPWpGaD
Carbamazepine—Hypersensitivity—Cyclosporine—psoriasis	5.55e-05	0.000231	CcSEcCtD
Carbamazepine—Dyspepsia—Triamcinolone—psoriasis	5.55e-05	0.000231	CcSEcCtD
Carbamazepine—Erythema multiforme—Methotrexate—psoriasis	5.54e-05	0.00023	CcSEcCtD
Carbamazepine—Nausea—Mycophenolic acid—psoriasis	5.53e-05	0.00023	CcSEcCtD
Carbamazepine—Hyperhidrosis—Betamethasone—psoriasis	5.53e-05	0.00023	CcSEcCtD
Carbamazepine—Hyperhidrosis—Dexamethasone—psoriasis	5.53e-05	0.00023	CcSEcCtD
Carbamazepine—Feeling abnormal—Hydrocortisone—psoriasis	5.52e-05	0.000229	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.51e-05	0.00189	CbGpPWpGaD
Carbamazepine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.5e-05	0.00188	CbGpPWpGaD
Carbamazepine—Vertigo—Prednisone—psoriasis	5.48e-05	0.000228	CcSEcCtD
Carbamazepine—Eye disorder—Methotrexate—psoriasis	5.47e-05	0.000228	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Hydrocortisone—psoriasis	5.47e-05	0.000228	CcSEcCtD
Carbamazepine—Syncope—Prednisone—psoriasis	5.47e-05	0.000227	CcSEcCtD
Carbamazepine—Tinnitus—Methotrexate—psoriasis	5.46e-05	0.000227	CcSEcCtD
Carbamazepine—Anorexia—Dexamethasone—psoriasis	5.45e-05	0.000227	CcSEcCtD
Carbamazepine—Anorexia—Betamethasone—psoriasis	5.45e-05	0.000227	CcSEcCtD
Carbamazepine—Urticaria—Prednisolone—psoriasis	5.44e-05	0.000226	CcSEcCtD
Carbamazepine—Cardiac disorder—Methotrexate—psoriasis	5.44e-05	0.000226	CcSEcCtD
Carbamazepine—Fatigue—Triamcinolone—psoriasis	5.43e-05	0.000226	CcSEcCtD
Carbamazepine—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.41e-05	0.000225	CcSEcCtD
Carbamazepine—Asthenia—Cyclosporine—psoriasis	5.4e-05	0.000225	CcSEcCtD
Carbamazepine—Pain—Triamcinolone—psoriasis	5.39e-05	0.000224	CcSEcCtD
Carbamazepine—Loss of consciousness—Prednisone—psoriasis	5.36e-05	0.000223	CcSEcCtD
Carbamazepine—Hypotension—Dexamethasone—psoriasis	5.34e-05	0.000222	CcSEcCtD
Carbamazepine—Hypotension—Betamethasone—psoriasis	5.34e-05	0.000222	CcSEcCtD
Carbamazepine—SCN9A—Developmental Biology—LEP—psoriasis	5.34e-05	0.00183	CbGpPWpGaD
Carbamazepine—Pruritus—Cyclosporine—psoriasis	5.33e-05	0.000221	CcSEcCtD
Carbamazepine—Urticaria—Hydrocortisone—psoriasis	5.32e-05	0.000221	CcSEcCtD
Carbamazepine—Angiopathy—Methotrexate—psoriasis	5.31e-05	0.000221	CcSEcCtD
Carbamazepine—Immune system disorder—Methotrexate—psoriasis	5.29e-05	0.00022	CcSEcCtD
Carbamazepine—Abdominal pain—Hydrocortisone—psoriasis	5.29e-05	0.00022	CcSEcCtD
Carbamazepine—Body temperature increased—Hydrocortisone—psoriasis	5.29e-05	0.00022	CcSEcCtD
Carbamazepine—Convulsion—Prednisone—psoriasis	5.29e-05	0.00022	CcSEcCtD
Carbamazepine—Mediastinal disorder—Methotrexate—psoriasis	5.28e-05	0.000219	CcSEcCtD
Carbamazepine—Asthenia—Mycophenolate mofetil—psoriasis	5.27e-05	0.000219	CcSEcCtD
Carbamazepine—Hypertension—Prednisone—psoriasis	5.27e-05	0.000219	CcSEcCtD
Carbamazepine—Chills—Methotrexate—psoriasis	5.26e-05	0.000218	CcSEcCtD
Carbamazepine—SCN4A—Axon guidance—TYK2—psoriasis	5.25e-05	0.0018	CbGpPWpGaD
Carbamazepine—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.21e-05	0.000217	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Betamethasone—psoriasis	5.21e-05	0.000217	CcSEcCtD
Carbamazepine—Pruritus—Mycophenolate mofetil—psoriasis	5.2e-05	0.000216	CcSEcCtD
Carbamazepine—Arthralgia—Prednisone—psoriasis	5.19e-05	0.000216	CcSEcCtD
Carbamazepine—Myalgia—Prednisone—psoriasis	5.19e-05	0.000216	CcSEcCtD
Carbamazepine—Feeling abnormal—Triamcinolone—psoriasis	5.19e-05	0.000216	CcSEcCtD
Carbamazepine—Anxiety—Prednisone—psoriasis	5.18e-05	0.000215	CcSEcCtD
Carbamazepine—Alopecia—Methotrexate—psoriasis	5.18e-05	0.000215	CcSEcCtD
Carbamazepine—Insomnia—Dexamethasone—psoriasis	5.17e-05	0.000215	CcSEcCtD
Carbamazepine—Insomnia—Betamethasone—psoriasis	5.17e-05	0.000215	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—JUN—psoriasis	5.17e-05	0.00177	CbGpPWpGaD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.16e-05	0.000214	CcSEcCtD
Carbamazepine—Diarrhoea—Cyclosporine—psoriasis	5.15e-05	0.000214	CcSEcCtD
Carbamazepine—Paraesthesia—Dexamethasone—psoriasis	5.13e-05	0.000213	CcSEcCtD
Carbamazepine—Paraesthesia—Betamethasone—psoriasis	5.13e-05	0.000213	CcSEcCtD
Carbamazepine—Mental disorder—Methotrexate—psoriasis	5.13e-05	0.000213	CcSEcCtD
Carbamazepine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.12e-05	0.00176	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.1e-05	0.00175	CbGpPWpGaD
Carbamazepine—Erythema—Methotrexate—psoriasis	5.1e-05	0.000212	CcSEcCtD
Carbamazepine—Malnutrition—Methotrexate—psoriasis	5.1e-05	0.000212	CcSEcCtD
Carbamazepine—Hypersensitivity—Prednisolone—psoriasis	5.05e-05	0.00021	CcSEcCtD
Carbamazepine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.04e-05	0.00173	CbGpPWpGaD
Carbamazepine—Dyspepsia—Dexamethasone—psoriasis	5.03e-05	0.000209	CcSEcCtD
Carbamazepine—Dyspepsia—Betamethasone—psoriasis	5.03e-05	0.000209	CcSEcCtD
Carbamazepine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.03e-05	0.000209	CcSEcCtD
Carbamazepine—UGT2B7—Metabolism—CYP2S1—psoriasis	5.02e-05	0.00172	CbGpPWpGaD
Carbamazepine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.02e-05	0.00172	CbGpPWpGaD
Carbamazepine—Urticaria—Triamcinolone—psoriasis	5.01e-05	0.000208	CcSEcCtD
Carbamazepine—Dysgeusia—Methotrexate—psoriasis	4.99e-05	0.000208	CcSEcCtD
Carbamazepine—Body temperature increased—Triamcinolone—psoriasis	4.98e-05	0.000207	CcSEcCtD
Carbamazepine—Dizziness—Cyclosporine—psoriasis	4.98e-05	0.000207	CcSEcCtD
Carbamazepine—Anaphylactic shock—Prednisone—psoriasis	4.98e-05	0.000207	CcSEcCtD
Carbamazepine—Oedema—Prednisone—psoriasis	4.98e-05	0.000207	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.97e-05	0.0017	CbGpPWpGaD
Carbamazepine—Decreased appetite—Betamethasone—psoriasis	4.97e-05	0.000207	CcSEcCtD
Carbamazepine—Decreased appetite—Dexamethasone—psoriasis	4.97e-05	0.000207	CcSEcCtD
Carbamazepine—Infection—Prednisone—psoriasis	4.95e-05	0.000206	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Betamethasone—psoriasis	4.94e-05	0.000205	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Dexamethasone—psoriasis	4.94e-05	0.000205	CcSEcCtD
Carbamazepine—Back pain—Methotrexate—psoriasis	4.93e-05	0.000205	CcSEcCtD
Carbamazepine—Hypersensitivity—Hydrocortisone—psoriasis	4.93e-05	0.000205	CcSEcCtD
Carbamazepine—Fatigue—Betamethasone—psoriasis	4.93e-05	0.000205	CcSEcCtD
Carbamazepine—Fatigue—Dexamethasone—psoriasis	4.93e-05	0.000205	CcSEcCtD
Carbamazepine—SCN4A—Developmental Biology—LEP—psoriasis	4.9e-05	0.00168	CbGpPWpGaD
Carbamazepine—Shock—Prednisone—psoriasis	4.9e-05	0.000204	CcSEcCtD
Carbamazepine—Pain—Dexamethasone—psoriasis	4.89e-05	0.000203	CcSEcCtD
Carbamazepine—Pain—Betamethasone—psoriasis	4.89e-05	0.000203	CcSEcCtD
Carbamazepine—Nervous system disorder—Prednisone—psoriasis	4.88e-05	0.000203	CcSEcCtD
Carbamazepine—Tachycardia—Prednisone—psoriasis	4.86e-05	0.000202	CcSEcCtD
Carbamazepine—Dizziness—Mycophenolate mofetil—psoriasis	4.86e-05	0.000202	CcSEcCtD
Carbamazepine—Skin disorder—Prednisone—psoriasis	4.84e-05	0.000201	CcSEcCtD
Carbamazepine—Hyperhidrosis—Prednisone—psoriasis	4.81e-05	0.0002	CcSEcCtD
Carbamazepine—Vision blurred—Methotrexate—psoriasis	4.81e-05	0.0002	CcSEcCtD
Carbamazepine—Asthenia—Hydrocortisone—psoriasis	4.8e-05	0.0002	CcSEcCtD
Carbamazepine—Vomiting—Cyclosporine—psoriasis	4.79e-05	0.000199	CcSEcCtD
Carbamazepine—Rash—Cyclosporine—psoriasis	4.75e-05	0.000197	CcSEcCtD
Carbamazepine—Anorexia—Prednisone—psoriasis	4.75e-05	0.000197	CcSEcCtD
Carbamazepine—Dermatitis—Cyclosporine—psoriasis	4.74e-05	0.000197	CcSEcCtD
Carbamazepine—Pruritus—Hydrocortisone—psoriasis	4.74e-05	0.000197	CcSEcCtD
Carbamazepine—Headache—Cyclosporine—psoriasis	4.72e-05	0.000196	CcSEcCtD
Carbamazepine—Anaemia—Methotrexate—psoriasis	4.71e-05	0.000196	CcSEcCtD
Carbamazepine—Feeling abnormal—Betamethasone—psoriasis	4.71e-05	0.000196	CcSEcCtD
Carbamazepine—Feeling abnormal—Dexamethasone—psoriasis	4.71e-05	0.000196	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Dexamethasone—psoriasis	4.68e-05	0.000194	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Betamethasone—psoriasis	4.68e-05	0.000194	CcSEcCtD
Carbamazepine—Vomiting—Mycophenolate mofetil—psoriasis	4.67e-05	0.000194	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.66e-05	0.0016	CbGpPWpGaD
Carbamazepine—SCN9A—Developmental Biology—PPARG—psoriasis	4.65e-05	0.00159	CbGpPWpGaD
Carbamazepine—Hypersensitivity—Triamcinolone—psoriasis	4.64e-05	0.000193	CcSEcCtD
Carbamazepine—Rash—Mycophenolate mofetil—psoriasis	4.63e-05	0.000193	CcSEcCtD
Carbamazepine—Dermatitis—Mycophenolate mofetil—psoriasis	4.63e-05	0.000192	CcSEcCtD
Carbamazepine—Headache—Mycophenolate mofetil—psoriasis	4.6e-05	0.000191	CcSEcCtD
Carbamazepine—Vertigo—Methotrexate—psoriasis	4.58e-05	0.00019	CcSEcCtD
Carbamazepine—Diarrhoea—Hydrocortisone—psoriasis	4.58e-05	0.00019	CcSEcCtD
Carbamazepine—Leukopenia—Methotrexate—psoriasis	4.56e-05	0.00019	CcSEcCtD
Carbamazepine—Urticaria—Dexamethasone—psoriasis	4.54e-05	0.000189	CcSEcCtD
Carbamazepine—Urticaria—Betamethasone—psoriasis	4.54e-05	0.000189	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Prednisone—psoriasis	4.54e-05	0.000189	CcSEcCtD
Carbamazepine—Dizziness—Prednisolone—psoriasis	4.53e-05	0.000188	CcSEcCtD
Carbamazepine—Asthenia—Triamcinolone—psoriasis	4.52e-05	0.000188	CcSEcCtD
Carbamazepine—Body temperature increased—Betamethasone—psoriasis	4.52e-05	0.000188	CcSEcCtD
Carbamazepine—Abdominal pain—Betamethasone—psoriasis	4.52e-05	0.000188	CcSEcCtD
Carbamazepine—Body temperature increased—Dexamethasone—psoriasis	4.52e-05	0.000188	CcSEcCtD
Carbamazepine—Abdominal pain—Dexamethasone—psoriasis	4.52e-05	0.000188	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.51e-05	0.00155	CbGpPWpGaD
Carbamazepine—Insomnia—Prednisone—psoriasis	4.5e-05	0.000187	CcSEcCtD
Carbamazepine—Nausea—Cyclosporine—psoriasis	4.47e-05	0.000186	CcSEcCtD
Carbamazepine—Paraesthesia—Prednisone—psoriasis	4.47e-05	0.000186	CcSEcCtD
Carbamazepine—Pruritus—Triamcinolone—psoriasis	4.46e-05	0.000185	CcSEcCtD
Carbamazepine—Dizziness—Hydrocortisone—psoriasis	4.43e-05	0.000184	CcSEcCtD
Carbamazepine—Convulsion—Methotrexate—psoriasis	4.42e-05	0.000184	CcSEcCtD
Carbamazepine—Dyspepsia—Prednisone—psoriasis	4.38e-05	0.000182	CcSEcCtD
Carbamazepine—Nausea—Mycophenolate mofetil—psoriasis	4.36e-05	0.000181	CcSEcCtD
Carbamazepine—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	4.35e-05	0.00149	CbGpPWpGaD
Carbamazepine—Arthralgia—Methotrexate—psoriasis	4.34e-05	0.00018	CcSEcCtD
Carbamazepine—Chest pain—Methotrexate—psoriasis	4.34e-05	0.00018	CcSEcCtD
Carbamazepine—Myalgia—Methotrexate—psoriasis	4.34e-05	0.00018	CcSEcCtD
Carbamazepine—Decreased appetite—Prednisone—psoriasis	4.33e-05	0.00018	CcSEcCtD
Carbamazepine—Rash—Prednisolone—psoriasis	4.32e-05	0.00018	CcSEcCtD
Carbamazepine—Dermatitis—Prednisolone—psoriasis	4.32e-05	0.000179	CcSEcCtD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.31e-05	0.000179	CcSEcCtD
Carbamazepine—Fatigue—Prednisone—psoriasis	4.29e-05	0.000178	CcSEcCtD
Carbamazepine—Headache—Prednisolone—psoriasis	4.29e-05	0.000178	CcSEcCtD
Carbamazepine—SCN4A—Developmental Biology—PPARG—psoriasis	4.27e-05	0.00146	CbGpPWpGaD
Carbamazepine—Constipation—Prednisone—psoriasis	4.26e-05	0.000177	CcSEcCtD
Carbamazepine—Vomiting—Hydrocortisone—psoriasis	4.26e-05	0.000177	CcSEcCtD
Carbamazepine—Rash—Hydrocortisone—psoriasis	4.22e-05	0.000175	CcSEcCtD
Carbamazepine—Dermatitis—Hydrocortisone—psoriasis	4.22e-05	0.000175	CcSEcCtD
Carbamazepine—Confusional state—Methotrexate—psoriasis	4.2e-05	0.000174	CcSEcCtD
Carbamazepine—Headache—Hydrocortisone—psoriasis	4.19e-05	0.000174	CcSEcCtD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.19e-05	0.00144	CbGpPWpGaD
Carbamazepine—Dizziness—Triamcinolone—psoriasis	4.17e-05	0.000173	CcSEcCtD
Carbamazepine—Anaphylactic shock—Methotrexate—psoriasis	4.16e-05	0.000173	CcSEcCtD
Carbamazepine—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	4.15e-05	0.00142	CbGpPWpGaD
Carbamazepine—Infection—Methotrexate—psoriasis	4.13e-05	0.000172	CcSEcCtD
Carbamazepine—Feeling abnormal—Prednisone—psoriasis	4.1e-05	0.000171	CcSEcCtD
Carbamazepine—Asthenia—Betamethasone—psoriasis	4.1e-05	0.000171	CcSEcCtD
Carbamazepine—Asthenia—Dexamethasone—psoriasis	4.1e-05	0.000171	CcSEcCtD
Carbamazepine—Nervous system disorder—Methotrexate—psoriasis	4.08e-05	0.00017	CcSEcCtD
Carbamazepine—Thrombocytopenia—Methotrexate—psoriasis	4.07e-05	0.000169	CcSEcCtD
Carbamazepine—SCN9A—Developmental Biology—TYK2—psoriasis	4.07e-05	0.0014	CbGpPWpGaD
Carbamazepine—Gastrointestinal pain—Prednisone—psoriasis	4.07e-05	0.000169	CcSEcCtD
Carbamazepine—Nausea—Prednisolone—psoriasis	4.07e-05	0.000169	CcSEcCtD
Carbamazepine—Pruritus—Dexamethasone—psoriasis	4.05e-05	0.000168	CcSEcCtD
Carbamazepine—Pruritus—Betamethasone—psoriasis	4.05e-05	0.000168	CcSEcCtD
Carbamazepine—Skin disorder—Methotrexate—psoriasis	4.04e-05	0.000168	CcSEcCtD
Carbamazepine—CYP3A7—Metabolism—NDUFA5—psoriasis	4.04e-05	0.00138	CbGpPWpGaD
Carbamazepine—SCN9A—Axon guidance—VEGFA—psoriasis	4.04e-05	0.00138	CbGpPWpGaD
Carbamazepine—Hyperhidrosis—Methotrexate—psoriasis	4.02e-05	0.000167	CcSEcCtD
Carbamazepine—Vomiting—Triamcinolone—psoriasis	4.01e-05	0.000167	CcSEcCtD
Carbamazepine—Nausea—Hydrocortisone—psoriasis	3.98e-05	0.000165	CcSEcCtD
Carbamazepine—Rash—Triamcinolone—psoriasis	3.97e-05	0.000165	CcSEcCtD
Carbamazepine—Dermatitis—Triamcinolone—psoriasis	3.97e-05	0.000165	CcSEcCtD
Carbamazepine—Anorexia—Methotrexate—psoriasis	3.97e-05	0.000165	CcSEcCtD
Carbamazepine—Urticaria—Prednisone—psoriasis	3.96e-05	0.000164	CcSEcCtD
Carbamazepine—Headache—Triamcinolone—psoriasis	3.95e-05	0.000164	CcSEcCtD
Carbamazepine—Abdominal pain—Prednisone—psoriasis	3.94e-05	0.000164	CcSEcCtD
Carbamazepine—Body temperature increased—Prednisone—psoriasis	3.94e-05	0.000164	CcSEcCtD
Carbamazepine—Diarrhoea—Betamethasone—psoriasis	3.91e-05	0.000163	CcSEcCtD
Carbamazepine—Diarrhoea—Dexamethasone—psoriasis	3.91e-05	0.000163	CcSEcCtD
Carbamazepine—Hypotension—Methotrexate—psoriasis	3.89e-05	0.000162	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—TNF—psoriasis	3.87e-05	0.00133	CbGpPWpGaD
Carbamazepine—Musculoskeletal discomfort—Methotrexate—psoriasis	3.79e-05	0.000158	CcSEcCtD
Carbamazepine—Dizziness—Betamethasone—psoriasis	3.78e-05	0.000157	CcSEcCtD
Carbamazepine—Dizziness—Dexamethasone—psoriasis	3.78e-05	0.000157	CcSEcCtD
Carbamazepine—Insomnia—Methotrexate—psoriasis	3.76e-05	0.000156	CcSEcCtD
Carbamazepine—SCN4A—Developmental Biology—TYK2—psoriasis	3.74e-05	0.00128	CbGpPWpGaD
Carbamazepine—Nausea—Triamcinolone—psoriasis	3.74e-05	0.000156	CcSEcCtD
Carbamazepine—Paraesthesia—Methotrexate—psoriasis	3.74e-05	0.000155	CcSEcCtD
Carbamazepine—Dyspnoea—Methotrexate—psoriasis	3.71e-05	0.000154	CcSEcCtD
Carbamazepine—SCN4A—Axon guidance—VEGFA—psoriasis	3.71e-05	0.00127	CbGpPWpGaD
Carbamazepine—Somnolence—Methotrexate—psoriasis	3.7e-05	0.000154	CcSEcCtD
Carbamazepine—Hypersensitivity—Prednisone—psoriasis	3.67e-05	0.000153	CcSEcCtD
Carbamazepine—Dyspepsia—Methotrexate—psoriasis	3.66e-05	0.000152	CcSEcCtD
Carbamazepine—RALBP1—Signaling Pathways—SOCS1—psoriasis	3.65e-05	0.00125	CbGpPWpGaD
Carbamazepine—Vomiting—Betamethasone—psoriasis	3.64e-05	0.000151	CcSEcCtD
Carbamazepine—Vomiting—Dexamethasone—psoriasis	3.64e-05	0.000151	CcSEcCtD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.62e-05	0.00124	CbGpPWpGaD
Carbamazepine—Decreased appetite—Methotrexate—psoriasis	3.62e-05	0.00015	CcSEcCtD
Carbamazepine—Rash—Betamethasone—psoriasis	3.61e-05	0.00015	CcSEcCtD
Carbamazepine—Rash—Dexamethasone—psoriasis	3.61e-05	0.00015	CcSEcCtD
Carbamazepine—Dermatitis—Dexamethasone—psoriasis	3.6e-05	0.00015	CcSEcCtD
Carbamazepine—Dermatitis—Betamethasone—psoriasis	3.6e-05	0.00015	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Methotrexate—psoriasis	3.59e-05	0.000149	CcSEcCtD
Carbamazepine—Fatigue—Methotrexate—psoriasis	3.59e-05	0.000149	CcSEcCtD
Carbamazepine—Headache—Betamethasone—psoriasis	3.58e-05	0.000149	CcSEcCtD
Carbamazepine—Headache—Dexamethasone—psoriasis	3.58e-05	0.000149	CcSEcCtD
Carbamazepine—Asthenia—Prednisone—psoriasis	3.57e-05	0.000149	CcSEcCtD
Carbamazepine—Pain—Methotrexate—psoriasis	3.56e-05	0.000148	CcSEcCtD
Carbamazepine—SCN5A—Axon guidance—TYK2—psoriasis	3.56e-05	0.00122	CbGpPWpGaD
Carbamazepine—Pruritus—Prednisone—psoriasis	3.52e-05	0.000146	CcSEcCtD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.48e-05	0.00119	CbGpPWpGaD
Carbamazepine—CYP3A7—Metabolism—CYP2S1—psoriasis	3.43e-05	0.00118	CbGpPWpGaD
Carbamazepine—Feeling abnormal—Methotrexate—psoriasis	3.43e-05	0.000143	CcSEcCtD
Carbamazepine—Diarrhoea—Prednisone—psoriasis	3.41e-05	0.000142	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—IFNG—psoriasis	3.4e-05	0.00117	CbGpPWpGaD
Carbamazepine—Gastrointestinal pain—Methotrexate—psoriasis	3.4e-05	0.000141	CcSEcCtD
Carbamazepine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.4e-05	0.00116	CbGpPWpGaD
Carbamazepine—Nausea—Dexamethasone—psoriasis	3.4e-05	0.000141	CcSEcCtD
Carbamazepine—Nausea—Betamethasone—psoriasis	3.4e-05	0.000141	CcSEcCtD
Carbamazepine—SCN5A—Developmental Biology—LEP—psoriasis	3.32e-05	0.00114	CbGpPWpGaD
Carbamazepine—Urticaria—Methotrexate—psoriasis	3.31e-05	0.000137	CcSEcCtD
Carbamazepine—Dizziness—Prednisone—psoriasis	3.29e-05	0.000137	CcSEcCtD
Carbamazepine—Body temperature increased—Methotrexate—psoriasis	3.29e-05	0.000137	CcSEcCtD
Carbamazepine—Abdominal pain—Methotrexate—psoriasis	3.29e-05	0.000137	CcSEcCtD
Carbamazepine—SCN9A—Developmental Biology—NFKB1—psoriasis	3.17e-05	0.00109	CbGpPWpGaD
Carbamazepine—Vomiting—Prednisone—psoriasis	3.17e-05	0.000132	CcSEcCtD
Carbamazepine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.16e-05	0.00108	CbGpPWpGaD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.16e-05	0.00108	CbGpPWpGaD
Carbamazepine—Rash—Prednisone—psoriasis	3.14e-05	0.000131	CcSEcCtD
Carbamazepine—Dermatitis—Prednisone—psoriasis	3.14e-05	0.00013	CcSEcCtD
Carbamazepine—SCN5A—SIDS Susceptibility Pathways—IL6—psoriasis	3.12e-05	0.00107	CbGpPWpGaD
Carbamazepine—Headache—Prednisone—psoriasis	3.12e-05	0.00013	CcSEcCtD
Carbamazepine—Hypersensitivity—Methotrexate—psoriasis	3.07e-05	0.000127	CcSEcCtD
Carbamazepine—Asthenia—Methotrexate—psoriasis	2.99e-05	0.000124	CcSEcCtD
Carbamazepine—CYP2B6—Metabolism—NDUFA5—psoriasis	2.99e-05	0.00102	CbGpPWpGaD
Carbamazepine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.97e-05	0.00102	CbGpPWpGaD
Carbamazepine—Nausea—Prednisone—psoriasis	2.96e-05	0.000123	CcSEcCtD
Carbamazepine—Pruritus—Methotrexate—psoriasis	2.94e-05	0.000122	CcSEcCtD
Carbamazepine—CYP3A5—Metabolism—NDUFA5—psoriasis	2.92e-05	0.001	CbGpPWpGaD
Carbamazepine—SCN4A—Developmental Biology—NFKB1—psoriasis	2.92e-05	0.001	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—PPARG—psoriasis	2.9e-05	0.000993	CbGpPWpGaD
Carbamazepine—SCN9A—Developmental Biology—VEGFA—psoriasis	2.88e-05	0.000987	CbGpPWpGaD
Carbamazepine—SCN9A—Developmental Biology—STAT3—psoriasis	2.85e-05	0.000978	CbGpPWpGaD
Carbamazepine—Diarrhoea—Methotrexate—psoriasis	2.85e-05	0.000118	CcSEcCtD
Carbamazepine—SCN9A—Axon guidance—IL6—psoriasis	2.79e-05	0.000957	CbGpPWpGaD
Carbamazepine—Dizziness—Methotrexate—psoriasis	2.75e-05	0.000114	CcSEcCtD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.71e-05	0.000929	CbGpPWpGaD
Carbamazepine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.71e-05	0.000929	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—APOE—psoriasis	2.69e-05	0.000923	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—LEP—psoriasis	2.69e-05	0.000923	CbGpPWpGaD
Carbamazepine—SCN4A—Developmental Biology—VEGFA—psoriasis	2.65e-05	0.000907	CbGpPWpGaD
Carbamazepine—Vomiting—Methotrexate—psoriasis	2.65e-05	0.00011	CcSEcCtD
Carbamazepine—Rash—Methotrexate—psoriasis	2.62e-05	0.000109	CcSEcCtD
Carbamazepine—Dermatitis—Methotrexate—psoriasis	2.62e-05	0.000109	CcSEcCtD
Carbamazepine—SCN4A—Developmental Biology—STAT3—psoriasis	2.62e-05	0.000898	CbGpPWpGaD
Carbamazepine—Headache—Methotrexate—psoriasis	2.61e-05	0.000108	CcSEcCtD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.61e-05	0.000893	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.57e-05	0.000881	CbGpPWpGaD
Carbamazepine—SCN4A—Axon guidance—IL6—psoriasis	2.57e-05	0.000879	CbGpPWpGaD
Carbamazepine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.54e-05	0.00087	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—TYK2—psoriasis	2.54e-05	0.00087	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.53e-05	0.000866	CbGpPWpGaD
Carbamazepine—SCN5A—Axon guidance—VEGFA—psoriasis	2.51e-05	0.000862	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—NFKBIA—psoriasis	2.51e-05	0.00086	CbGpPWpGaD
Carbamazepine—CYP3A5—Metabolism—CYP2S1—psoriasis	2.48e-05	0.000851	CbGpPWpGaD
Carbamazepine—Nausea—Methotrexate—psoriasis	2.47e-05	0.000103	CcSEcCtD
Carbamazepine—SCN9A—Developmental Biology—TNF—psoriasis	2.47e-05	0.000846	CbGpPWpGaD
Carbamazepine—UGT2B7—Metabolism—CARM1—psoriasis	2.45e-05	0.000841	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.36e-05	0.000808	CbGpPWpGaD
Carbamazepine—SCN4A—Developmental Biology—TNF—psoriasis	2.27e-05	0.000778	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.26e-05	0.000773	CbGpPWpGaD
Carbamazepine—ABCB1—Allograft Rejection—TNF—psoriasis	2.2e-05	0.000755	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—NDUFA5—psoriasis	2.2e-05	0.000755	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.19e-05	0.000751	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.15e-05	0.000737	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.1e-05	0.000721	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.06e-05	0.000705	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—TYK2—psoriasis	2.05e-05	0.000704	CbGpPWpGaD
Carbamazepine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.05e-05	0.000702	CbGpPWpGaD
Carbamazepine—SCN9A—Developmental Biology—IL6—psoriasis	1.99e-05	0.000683	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—NFKB1—psoriasis	1.98e-05	0.000678	CbGpPWpGaD
Carbamazepine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.95e-05	0.000669	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.92e-05	0.000658	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.92e-05	0.000658	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—CYP2S1—psoriasis	1.87e-05	0.000642	CbGpPWpGaD
Carbamazepine—SCN4A—Developmental Biology—IL6—psoriasis	1.83e-05	0.000628	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—VEGFA—psoriasis	1.79e-05	0.000615	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—CXCL8—psoriasis	1.79e-05	0.000613	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—STAT3—psoriasis	1.78e-05	0.000609	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.76e-05	0.000603	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.75e-05	0.0006	CbGpPWpGaD
Carbamazepine—SCN5A—Axon guidance—IL6—psoriasis	1.74e-05	0.000596	CbGpPWpGaD
Carbamazepine—CYP3A7—Metabolism—CARM1—psoriasis	1.68e-05	0.000575	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—JUN—psoriasis	1.66e-05	0.00057	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.64e-05	0.000562	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—NFKB1—psoriasis	1.6e-05	0.000549	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—TNF—psoriasis	1.54e-05	0.000527	CbGpPWpGaD
Carbamazepine—UGT2B7—Metabolism—CAT—psoriasis	1.51e-05	0.000517	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.49e-05	0.000512	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—VEGFA—psoriasis	1.45e-05	0.000498	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.45e-05	0.000498	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—STAT3—psoriasis	1.44e-05	0.000493	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.4e-05	0.000479	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.36e-05	0.000465	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.27e-05	0.000435	CbGpPWpGaD
Carbamazepine—SCN5A—Developmental Biology—IL6—psoriasis	1.24e-05	0.000425	CbGpPWpGaD
Carbamazepine—CYP2B6—Metabolism—CARM1—psoriasis	1.24e-05	0.000425	CbGpPWpGaD
Carbamazepine—CYP3A5—Metabolism—CARM1—psoriasis	1.21e-05	0.000415	CbGpPWpGaD
Carbamazepine—UGT2B7—Metabolism—APOE—psoriasis	1.17e-05	0.000402	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.15e-05	0.000395	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.13e-05	0.000386	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—TP53—psoriasis	1.1e-05	0.000376	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.09e-05	0.000373	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—CARM1—psoriasis	1.05e-05	0.00036	CbGpPWpGaD
Carbamazepine—CYP3A7—Metabolism—CAT—psoriasis	1.03e-05	0.000353	CbGpPWpGaD
Carbamazepine—UGT2B7—Metabolism—PPARG—psoriasis	1.02e-05	0.00035	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.01e-05	0.000345	CbGpPWpGaD
Carbamazepine—RALBP1—Signaling Pathways—IL6—psoriasis	1e-05	0.000345	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.81e-06	0.000336	CbGpPWpGaD
Carbamazepine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.58e-06	0.000329	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—CARM1—psoriasis	9.37e-06	0.000321	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.17e-06	0.000314	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—CARM1—psoriasis	9.14e-06	0.000313	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.76e-06	0.0003	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—CARM1—psoriasis	8.54e-06	0.000293	CbGpPWpGaD
Carbamazepine—CYP3A7—Metabolism—APOE—psoriasis	8.01e-06	0.000275	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.98e-06	0.000274	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.83e-06	0.000269	CbGpPWpGaD
Carbamazepine—CYP2B6—Metabolism—CAT—psoriasis	7.63e-06	0.000261	CbGpPWpGaD
Carbamazepine—CYP3A5—Metabolism—CAT—psoriasis	7.45e-06	0.000256	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—CARM1—psoriasis	7.3e-06	0.00025	CbGpPWpGaD
Carbamazepine—CYP3A7—Metabolism—PPARG—psoriasis	6.98e-06	0.000239	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.82e-06	0.000234	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—CAT—psoriasis	6.46e-06	0.000221	CbGpPWpGaD
Carbamazepine—CYP2B6—Metabolism—APOE—psoriasis	5.93e-06	0.000203	CbGpPWpGaD
Carbamazepine—CYP3A5—Metabolism—APOE—psoriasis	5.79e-06	0.000199	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—CAT—psoriasis	5.76e-06	0.000198	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—CARM1—psoriasis	5.63e-06	0.000193	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—CAT—psoriasis	5.62e-06	0.000193	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—CAT—psoriasis	5.25e-06	0.00018	CbGpPWpGaD
Carbamazepine—CYP2B6—Metabolism—PPARG—psoriasis	5.16e-06	0.000177	CbGpPWpGaD
Carbamazepine—CYP3A5—Metabolism—PPARG—psoriasis	5.04e-06	0.000173	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—APOE—psoriasis	5.02e-06	0.000172	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—CAT—psoriasis	4.49e-06	0.000154	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—APOE—psoriasis	4.48e-06	0.000153	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—APOE—psoriasis	4.37e-06	0.00015	CbGpPWpGaD
Carbamazepine—CYP2C8—Metabolism—PPARG—psoriasis	4.37e-06	0.00015	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—APOE—psoriasis	4.08e-06	0.00014	CbGpPWpGaD
Carbamazepine—CYP2C19—Metabolism—PPARG—psoriasis	3.9e-06	0.000134	CbGpPWpGaD
Carbamazepine—ABCB1—Metabolism—PPARG—psoriasis	3.81e-06	0.00013	CbGpPWpGaD
Carbamazepine—CYP2C9—Metabolism—PPARG—psoriasis	3.56e-06	0.000122	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—APOE—psoriasis	3.49e-06	0.00012	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—CAT—psoriasis	3.47e-06	0.000119	CbGpPWpGaD
Carbamazepine—CYP1A2—Metabolism—PPARG—psoriasis	3.04e-06	0.000104	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—APOE—psoriasis	2.69e-06	9.23e-05	CbGpPWpGaD
Carbamazepine—CYP3A4—Metabolism—PPARG—psoriasis	2.35e-06	8.04e-05	CbGpPWpGaD
